After World War II, epidemics of Pneumocystis carinii pneumonitis occurred in Central Europe but were limited to debilitated and marasmic infants. The disease was first recognized in the United States in 1955 (11) and 1956 (2) , and since then has been reported with increasing frequency. The disease has occurred in the United States almost exclusively in patients with lymphoproliferative malignancies, organ transplants, congenital immunodeficiency disorders, and certain vascular disorders.
P. carinii pneumonitis expressed in the immunosuppressed host results in a mortality rate of approximately 100% it untreated (19) . Pentamidine isethionate is presently considered to be the drug of choice for the treatment of this infection. The mortality rate has been reduced to as low as 32% by daily injections of pentamidine (9) . However, pentamidine has a number of disadvantages: it has a relatively high therapeutic failure rate; it must be administered intramuscularly; clinical response is slow; it is not commercially available in the United States; and it is associated with undesirable toxic effects (impaired renal function, local tissue necrosis, hypoglycemia, and folic acid deficiency). Thus, search for a more effective and less toxic agent is warranted. Furthermore, it would be desirable to have a safe means of prophylaxis for use during times of high risk in immunosuppressed patients.
Pyrimethamine plus sulfonamides have been shown to have some effect against P. carinii (4, 13) although prophylactic usage has produced contradictory results (8, 13) . The cortisone-treated rat provides an excellent animal model for the study of P. carinii infection (4) . The pneumonitis occurs spontaneously in 80 to 100% of the animals after prolonged immunosuppression with cortisone. The mode of transmission and details of endogenous latency of this organism are not known. Although the taxonomy of P. carinii has not been defined, it is most likely a protozoan. Three drugs, not previously investigated for effectiveness against P. carinii but with possible antiprotozoan activity, were studied in the cortisone-treated rat model.
The combination of trimethoprim and sulfamethoxazole has been effective in the treatment of patients with P. falciparum malaria (3).
The mode of action is similar to that of pyrimethamine and sulfadiazine. Sulfamethoxazole acts by competitively inhibiting the incorporation of para-aminobenzoic acid into dihydrofolate. Trimethoprim inhibits dihydrofolate reductase, the enzyme which reduces dihydrofolic acid to tetrahydrofolic acid, an early stage in the process leading to the formation of purines and eventually deoxyribonucleic acid (DNA).
Clindamycin has been demonstrated to be effective against acute toxoplasmosis (12) and malaria (10) in animals. This drug acts as an inhibitor of protein synthesis.
Rifampin has been reported to be effective in preventing the multiplication of Toxoplasma gondii in L-cell culture (16 Rifampin (Rimactane, Ciba Pharmaceutical Co.) was given in the dosage of 10 mg per rat per day (50 mg/kg). The drug was given orally to the animals treated prophylactically and subcutaneously in the same dose given to animals treated after infection was established.
Tetracycline hydrochloride (15 mg per rat per day; 75 mg/kg) was administered only to cortisone-treated control rats (group 2) to prevent bacterial infection.
The cause of death was determined by histological examination of the lungs with hematoxylin-eosin-and methenamine-silver nitrate-stained sections. P. carinii pneumonitis was considered the cause of death when the extent of infection was stage III and evidence of bacterial, fungal, and viral infections was lacking. Bacterial pneumonitis was defined as extensive areas of acute inflammatory reactions to bacterial invasion of pulmonary parenchyma. When infection from more than one organism was present and none clearly predominant, the cause of death was attributed to the mixed infection. When yeast or hyphal forms only were found in areas of extensive inflammatory response, the cause of death was considered to be of fungal origin. Pneumonitis associated with intranuclear or intracytoplasmic inclusions was categorized as viral infection. No attempt was made to identify the bacterial, fungal, or viral agents.
Orally administered drugs were prepared daily and given in a limited volume of drinking water or by gavage if the total dose was not consumed. Rifampin, clindamycin, and trimethoprim-sulfamethoxazole were given as a single daily dose. 
RESULTS
All of the cortisone-treated animals had progressive weight loss, whereas incremental weight gains were observed in the control rats not receiving the immunosuppressive drug. Weight was not influenced by the type of antimicrobial agent administered ( Table 1) .
The control rats not receiving cortisone (group 1) remained healthy throughout the experiment, and P. carinii was not found in the lung sections from any of these 15 animals.
The cortisone-treated control rats (group 2) died between days 59 and 97 (median day, 78) ( Fig. 1) . All had extensive stage III P. carinii pneumonitis ( Table 1) .
P. carinii was not found in any of the lung sections from the animals treated prophylactically with trimethoprim-sulfamethoxazole ( Table 1) .
Of the 14 anirnals treated with trimethoprimsulfamethoxazole after death of the index animal from P. carinii pneumonitis, five died with some evidence of P. carinii infection ( Table 1) . Two of the animals died within 2 days after initiation of therapy and had stage III infection, one died after 12 days of treatment with bacterial pneumonia but had stage I P. carinii infection, and two animals died on days 13 and 16, respectively, with stage II P. carinii pneumonitis (Fig. 1) . Of the nine animals without P. carinii infection, spontaneous deaths occurred on days 28, 31, 115, 117 in four animals, respectively, and the five animals surviving on day 124 were sacrificed.
All animals readily accepted trimethoprimsulfamethoxazole supplied in drinking water. There were no apparent adverse or toxic effects. Folic acid levels were not determined. Histological examination of the kidneys of animals who received trimethoprim-sulfamethoxazole for as long as 124 days showed no evidence of abnormality.
The first death from P. carinii pneumonitis occurred on day 68 of cortisone treatment in group 5. Of the 14 rats treated for 2 weeks with pentamidine, deaths occurred from day 70 to 124 (median day, 77) ( Fig. 2) . Extensive necrotic areas occurred in the skin, subcutaneous tissue, and muscles where injections were given. Extremity paresis and impairment of mobility were obvious in these animals.
The pentamidine therapeutically, had survival times equal to or less than those of the untreated cortisone control animals. The incidence of P. carinii pneumonitis in these groups ranged from 80 to 100%.
The causes of deaths based on histological examination of lungs were determined. Group 1 (control, no cortisone) animals were sacrificed, and no significant evidence of infection was found. All of group 2 (cortisone controls, untreated) died with extensive stage III pneumonitis with little or no evidence of secondary infection. This group received tetracycline. Group 4 (trimethoprim-sulfamethoxazole, therapy) had three deaths from extensive P. carinii pneumonitis, three from mixed P. carinii, but predominantly bacterial, infection, and four from bacterial infection. Two of the five survivors had mild to moderately extensive bacterial pneumonitis at the time of sacrifice. The pentamidine-treated group 5 had eight deaths from P. carinii pneumonia, five from mixed bacterial and P. carinii infections, one from bacterial pneumonia, and one without infection. In group 3 (trimethoprim-sulfamethoxazole, prophylaxis), six died from bacterial pneumonia, one died from fungal (yeast) infection, two died from pneumonitis associated with viral inclusions, and in six the cause of death was not apparent.
The causes of deaths in the groups receiving clindamycin or rifampin, separately or with pentamidine, were similar to those of group 5 treated with pentamidine. DISCUSSION Under the conditions of these experiments, the trimethoprim-sulfamethoxazole combination is effective in the prevention and treatment of P. carinii pneumonitis in the rat. When compared with pentamidine, trimethoprim-sulfamethoxazole is more effective therapeutically. Although the index animal in the pentamidinetreated group died 10 days later than the index animal in the trimethoprim-sulfamethoxazoletreated group, the animals in both groups were comparable as to weights and general appearance at the time treatments were begun. Furthermore, six of the pentamidine-treated animals died with P. carinii pneumonitis after receiving at least 10 days of treatment. Earlier administration or higher dosage of pentamidine might have improved the survival rates; however, the dosage used was the same as that shown to be effective in the treatment of P. carinii infection in humans (19) and rats (4) and in patients with trypanosomiasis. The extensive necrosis at injection sites encountered in our study, as well as others (4, 8) , precludes the administration of pentamidine over prolonged periods of time. Frenkel et al. (4) found that the prophylactic use of pyrimethamine and sulfadiazine in rats had a more prolonged effect than pentamidine. Post et al. (13) were able to prevent P. carinii pneumonitis in infants under epidemic conditions by the administration of pyrimethamine and sulfadoxine. Pyrimethamine interferes with the conversion of folic to folinic acid.
In addition to therapeutic efficacy, trimethoprim-sulfamethoxazole offers the advantages of less toxicity than pentamidine, the potential for prolonged administration for prophylactic use, and oral route of administration in widely separated doses. Rats treated for 6 months with 100 mg of trimethoprim per kg per day and 400 mg of sulfamethoxazole per kg per day had no evidence of significant effects on leukocytes, platelets, and erythrocytes. However, a threefold increase in dosage caused "slight to moderate falls" in erythrocyte and platelet counts (18) .
Immunosuppressive effects of trimethoprimsulfamethoxazole have been suggested by studies which have shown impairment of phytohemagglutinin-induced lymphocyte transformation (5), prolongation of skin allograph survival in mice (6), suppression of hypersensitivity to dinitrochlorobenzene (7) , and suppression of antibody response in man (1). These parameters could not be investigated in the already immunosuppressed rats in our study.
In P. carinii pneumonitis, the organisms are found in abundance in the cytoplasm of alveolar macrophages (9) . One study has suggested that trimethoprim-sulfamethoxazole has a stimulating effect on granulocyte metabolism (14) . Sig-ANTIMICROB. AG. CHEMOTHER.
on June 28, 2017 by guest http://aac.asm.org/ Downloaded from nificant increases in measurable hydrogen peroxide production and oxygen uptake were obtained during phagocytosis of heat-killed Staphylococcus aureus by granulocytes of normal individuals as well as those from a patient with chronic granulomatous disease. This observation deserves further study, especially with the alveolar macrophage and P. carinii.
Pharmacokinetic studies of trimethoprim and sulfamethoxazole have demonstrated high concentrations of these drugs in the lungs of rats treated orally. Trimethoprim and sulfamethoxazole levels in lung tissue were two to three times those of plasma (17) . Since with fatal P. carinii infection the organisms remained localized to the lungs, an antimicrobial agent with high perfusion capabilities of this organ is desirable.
Higher doses of trimethoprim and sulfamethoxazole than those used in this study would likely be tolerated without significant toxic effects and might perhaps be more effective in the treatment of P. carinii infection. Although trimethoprim and sulfamethoxazole were not studied separately, studies with other organisms (15) indicate that synergism occurs with a broad spectrum of organisms. Furthermore, pyrimethamine combined with sulfadiazine (4) was more effective with P. carinii infection than was either of these drugs alone.
In conclusion, our studies show that trimethoprim-sulfamethoxazole is an effective antimicrobial regimen for the prevention and treatment of murine P. carinii pneumonitis. Clinical studies with these drugs are warranted.
